Seelos Therapeutics Operating Income 2010-2022 | SEEL
Seelos Therapeutics operating income from 2010 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Seelos Therapeutics Annual Operating Income
(Millions of US $) |
| 2021 |
$-62 |
| 2020 |
$-19 |
| 2019 |
$-30 |
| 2018 |
$-3 |
| 2017 |
$-11 |
| 2016 |
$-14 |
| 2015 |
$-21 |
| 2014 |
$-23 |
| 2013 |
$-17 |
| 2012 |
$-25 |
| 2011 |
$-18 |
| 2010 |
$-21 |
| 2009 |
$-3 |
Seelos Therapeutics Quarterly Operating Income
(Millions of US $) |
| 2022-03-31 |
$-14 |
| 2021-12-31 |
$-27 |
| 2021-09-30 |
$-11 |
| 2021-06-30 |
$-7 |
| 2021-03-31 |
$-17 |
| 2020-12-31 |
$-6 |
| 2020-09-30 |
$-4 |
| 2020-06-30 |
$-3 |
| 2020-03-31 |
$-6 |
| 2019-12-31 |
$-10 |
| 2019-09-30 |
$-4 |
| 2019-06-30 |
$-3 |
| 2019-03-31 |
$-12 |
| 2018-12-31 |
$-1 |
| 2018-09-30 |
$-1 |
| 2018-06-30 |
$-0 |
| 2018-03-31 |
$-1 |
| 2017-12-31 |
$-3 |
| 2017-09-30 |
$-4 |
| 2017-06-30 |
$-2 |
| 2017-03-31 |
$-2 |
| 2016-12-31 |
$-3 |
| 2016-09-30 |
$-2 |
| 2016-06-30 |
$-5 |
| 2016-03-31 |
$-5 |
| 2015-12-31 |
$-4 |
| 2015-09-30 |
$-6 |
| 2015-06-30 |
$-6 |
| 2015-03-31 |
$-6 |
| 2014-12-31 |
$-17 |
| 2014-09-30 |
$-3 |
| 2014-06-30 |
$1 |
| 2014-03-31 |
$-4 |
| 2013-12-31 |
$-4 |
| 2013-09-30 |
$-3 |
| 2013-06-30 |
$-4 |
| 2013-03-31 |
$-6 |
| 2012-12-31 |
$-15 |
| 2012-09-30 |
$-2 |
| 2012-06-30 |
$-4 |
| 2012-03-31 |
$-4 |
| 2011-12-31 |
$-4 |
| 2011-09-30 |
$-2 |
| 2011-06-30 |
$-8 |
| 2011-03-31 |
$-3 |
| 2010-12-31 |
$1 |
| 2010-09-30 |
$1 |
| 2010-06-30 |
$-3 |
| 2010-03-31 |
$-2 |
| 2009-12-31 |
$-2 |
| 2009-09-30 |
$-1 |
| 2009-06-30 |
$-1 |
| 2009-03-31 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.069B |
$0.000B |
|
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
|
